At MPC Therapeutics, we are convinced that mitochondria, the small organelles at the core of the cell's metabolism, represent untapped therapeutic targets. Headquartered in Switzerland, our startup is focused on cellular rejuvenation to improve the performance of cell therapies and treat degenerative pathologies. Our novel approach uses proprietary first-in-class small molecules that specifically target mitochondria to trigger metabolic reprogramming. Visit our website for more info.
| Website | http://www.mpc-therapeutics.com |
| Employees | 7 (2 on RocketReach) |
| Founded | 2018 |
| Address | Chemin des Aulx 14, Plan-les-Ouates, Geneva 1228, CH |
| Industry | Biotechnology Research |
| Keywords | Cellular Repair, Cellular Rejuvenation, Small Molecule Therapeutics, Regenerative Medicine, Mitochondrial Dysfunction, Therapeutic Targets, Aging Research, Bioenergetics, Cellular Health, Mitochondrial Health, Anti-Aging Therapies, Energy Metabolism, Disease Prevention, Longevity Research |
| Competitors | Amgen, Novartis, Gilead Sciences, Johnson & Johnson, Vertex Pharmaceuticals, Genentech, Biogen, Regeneron, Receptos, a wholly-owned subsidiary of Celgene, Lilly India +39 more (view full list) |
Looking for a particular MPC Therapeutics employee's phone or email?
Raphaël Martinou is the CEO and Co-Founder of MPC Therapeutics.
2 people are employed at MPC Therapeutics.
MPC Therapeutics is based in Plan-les-Ouates, Geneva.